Evidence map›Paper›PMID 35629235›Full record

ReviewJournal of personalized medicine2022

Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities.

Margherita Fabbri, Miguel Coelho, Michela Garon, Roberta Biundo, Tiago A Mestre, Angelo Antonini, On Behalf Of iCARE-Pd Consortium

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multidisciplinary care in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Margherita FabbriDepartment of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson Toulouse Expert Centre, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital, INSERM, University of Toulouse 3, 31062 Toulouse, France.ORCID 0000-0001-7250-592X
Miguel CoelhoInstituto de Medicina Molecular João Lobo Antunes, 1649-028 Lisboa, Portugal.ORCID 0000-0002-4008-8110
Michela GaronParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, 35131 Padova, Italy.
Roberta BiundoDepartment of General Psychology, University of Padova, 35131 Padova, Italy.
Tiago A MestreParkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, ON K1Y 4E9, Canada.
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, 35131 Padova, Italy.ORCID 0000-0003-1040-2807
On Behalf Of iCARE-Pd Consortium
University of Padua · ITInserm · FRInstituto de Medicina Molecular João Lobo AntunesUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-stage Parkinson's disease (LSPD) patients are highly dependent on activities of daily living and require significant medical needs. In LSPD, there is a significant caregiver burden and greater health economic impact compared to earlier PD stages. The clinical presentation in LSPD is dominated by motor and non-motor symptoms (NMS) that most of the time have a sub-optimal to no response to dopaminergic treatment, especially when dementia is present. Non-pharmacological interventions, including physiotherapy, cognitive stimulation, speech, occupational therapy, and a specialized PD nurse, assume a key role in LSPD to mitigate the impact of disease milestones or prevent acute clinical worsening and optimize the management of troublesome NMS. However, the feasibility of these approaches is limited by patients' cognitive impairment and the difficulty in delivering care at home. The present care challenge for LSPD is the ability to offer a person-centered, home-delivered palliative care model based on Advanced Care Planning. An ongoing European multicentric project, PD_Pal, aims to address this challenge.

Indexed as

caregivercognitive impairmenthome carelate stagepalliative careParkinson’s disease

Identifiers

PMID35629235
PMCPMC9147917
OpenAlexW4280637761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.